Inchingolo Riccardo, Pierandrei Chiara, Montemurro Giuliano, Smargiassi Andrea, Lohmeyer Franziska Michaela, Rizzi Angela
UOC Pneumologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Direzione Scientifica, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Antibiotics (Basel). 2021 Mar 20;10(3):326. doi: 10.3390/antibiotics10030326.
Non-cystic fibrosis bronchiectasis is a chronic disorder in which immune system dysregulation and impaired airway clearance cause mucus accumulation and consequent increased susceptibility to lung infections. The presence of pathogens in the lower respiratory tract causes a vicious circle resulting in impaired mucociliary function, bronchial inflammation, and progressive lung injury. In current guidelines, antibiotic therapy has a key role in bronchiectasis management to treat acute exacerbations and chronic infection and to eradicate bacterial colonization. Contrastingly, antimicrobial resistance, with the risk of multidrug-resistant pathogen development, causes nowadays great concern. The aim of this literature review was to assess the role of antibiotic therapy in bronchiectasis patient management and possible concerns regarding antimicrobial resistance based on current evidence. The authors of this review stress the need to expand research regarding bronchiectasis with the aim to assess measures to reduce the rate of antimicrobial resistance worldwide.
非囊性纤维化支气管扩张症是一种慢性疾病,其中免疫系统失调和气道清除功能受损会导致黏液积聚,进而增加肺部感染的易感性。下呼吸道病原体的存在会导致恶性循环,导致黏液纤毛功能受损、支气管炎症和进行性肺损伤。在当前指南中,抗生素治疗在支气管扩张症的管理中起着关键作用,用于治疗急性加重期和慢性感染以及根除细菌定植。相比之下,抗菌药物耐药性以及多重耐药病原体产生的风险,如今引起了极大关注。这篇文献综述的目的是根据现有证据评估抗生素治疗在支气管扩张症患者管理中的作用以及对抗菌药物耐药性的可能担忧。这篇综述的作者强调需要扩大关于支气管扩张症的研究,以评估在全球范围内降低抗菌药物耐药率的措施。